Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024
2024年9月18日 - 2:32AM
ビジネスワイヤ(英語)
Late-breaking oral presentation will discuss
the potential of ZL-1503 as a novel treatment for
moderate-to-severe atopic dermatitis and other diseases involving
the IL-13 and IL-31 pathways
ZL-1503 is part of Zai Lab’s internally
discovered and developed global pipeline
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688; “Zai Lab”) today
announced that data from a preclinical study of ZL-1503, the
company’s internally discovered IL-13/IL-31 bispecific antibody for
the treatment of atopic dermatitis (AD), will be presented in a
late-breaking oral presentation at the European Academy of
Dermatology and Venerology Congress (EADV) 2024 taking place
September 25-28 in Amsterdam, Netherlands. The results will address
the potential of ZL-1503 as a novel treatment for
moderate-to-severe atopic dermatitis, as well as other diseases
involving the IL-13 and IL-31 pathways.
Medications that inhibit IL-4/IL-13 signaling have markedly
improved the therapeutic landscape for AD. However, certain AD
symptoms are mediated by IL-31, which is only partially attenuated
by IL-4/IL-13 inhibition. As a result, many patients experience
slow and modest clinical responses to currently available
medications. Zai is evaluating the potential of ZL-1503 to inhibit
both IL-13 and IL-31 signaling pathways.
“The potential to simultaneously target both inflammatory and
pruritogenic pathways is important as it expands treatment options
for individuals with atopic dermatitis and other related
conditions,” said Rafael G. Amado, M.D., President, Head of Global
Research and Development, Zai Lab. “We look forward to sharing
preliminary results from our preclinical study of ZL-1503 at EADV
2024.”
Details regarding the ZL-1503 oral presentation at EADV 2024
are as follows:
Title: ZL-1503, a Bispecific, Serum Half-life Extended
Antibody Targeting Both Inflammatory and Pruritogenic Pathways for
Atopic Dermatitis and Other IL-13/IL-31 Related Diseases
Abstract Number: 7744
Presenter: Linda N. Liu, Senior Vice President, Biologics
Discovery, Zai Lab
Presentation date and time: Wednesday, September 25,
2024, 2:30-2:45 p.m. CEST
Session code and title: D1T01.1: Late breaking news
Session room: Auditorium
About Zai Lab
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative,
research-based, commercial-stage biopharmaceutical company based in
China and the United States. We are focused on discovering,
developing, and commercializing innovative products that address
medical conditions with significant unmet needs in the areas of
oncology, immunology, neuroscience, and infectious disease. Our
goal is to leverage our competencies and resources to positively
impact human health in China and worldwide.
For additional information about Zai Lab, please visit
www.zailaboratory.com or follow us at
www.twitter.com/ZaiLab_Global.
Zai Lab Forward-Looking Statements
This press release contains forward-looking statements relating
to our future expectations, plans, and prospects, including,
without limitation, statements regarding product candidates in our
pipeline including ZL-1503 and related preclinical studies; the
potential benefits of ZL-1503; and the potential treatment of
atopic dermatitis and other diseases involving the IL-13 and IL-31
pathways. All statements, other than statements of historical fact,
included in this press release are forward-looking statements, and
can be identified by words such as “aim,” “anticipate,” “believe,”
“could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,”
“plan,” “possible,” “potential,” “will,” “would,” and other similar
expressions. Such statements constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are not statements of
historical fact or guarantees or assurances of future performance.
Forward-looking statements are based on our expectations and
assumptions as of the date of this press release and are subject to
inherent uncertainties, risks, and changes in circumstances that
may differ materially from those contemplated by the
forward-looking statements. We may not actually achieve the plans,
carry out the intentions, or meet the expectations or projections
disclosed in our forward-looking statements, and you should not
place undue reliance on these forward-looking statements. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including but not limited to (1) our ability to
successfully commercialize and generate revenue from our approved
products, (2) our ability to obtain funding for our operations and
business initiatives, (3) the results of our clinical and
pre-clinical development of our product candidates, (4) the content
and timing of decisions made by the relevant regulatory authorities
regarding regulatory approvals of our product candidates, (5) risks
related to doing business in China, and (6) other factors
identified in our most recent annual and quarterly reports and in
other reports we have filed with the U.S. Securities and Exchange
Commission (SEC). We anticipate that subsequent events and
developments will cause our expectations and assumptions to change,
and we undertake no obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise, except as may be required by law.
These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release.
Our SEC filings can be found on our website at
www.zailaboratory.com and the SEC’s website at www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240917669591/en/
Investor Relations: Christine Chiou / Lina Zhang +1 (917)
886-6929 / +86 136 8257 6943 christine.chiou1@zailaboratory.com /
lina.zhang@zailaboratory.com
Media: Shaun Maccoun/ Xiaoyu Chen +1 (857) 270-8854 / +86
185 0015 5011 shaun.maccoun@zailaboratory.com /
xiaoyu.chen@zailaboratory.com
Zai Lab (NASDAQ:ZLAB)
過去 株価チャート
から 9 2024 まで 10 2024
Zai Lab (NASDAQ:ZLAB)
過去 株価チャート
から 10 2023 まで 10 2024